| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 54,178 | 55,703 | ||
| General and administrative | 17,100 | 17,462 | ||
| Total operating expenses | 71,278 | 73,165 | ||
| Loss from operations | -71,278 | -73,165 | ||
| Interest income, net | 6,318 | 7,141 | ||
| Total other income, net | 6,318 | 7,141 | ||
| Net loss before taxes | -64,960 | -66,024 | ||
| Provision for income taxes | 61 | 72 | ||
| Net loss after taxes | -65,021 | -66,096 | ||
| Earnings per share, basic | -1.11 | -1.13 | ||
| Earnings per share, diluted | -1.11 | -1.13 | ||
| Weighted average number of shares outstanding, basic | 58,773,731 | 58,428,344 | ||
| Weighted average number of shares outstanding, diluted | 58,773,731 | 58,428,344 | ||
Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc. (APGE)